Intellect Neurosciences, ViroPharma enter OX1 licensing agreement
Intellect will transfer all of Intellect’s intellectual property rights and data related to OX1 research and development program, to ViroPharma for $6.5m up-front licensing fee. The agreement has
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.